Cargando…
Prescription of Direct Oral Anticoagulants to Patients With Moderate-to-Advanced CKD: Too Little or Just Right?
Autores principales: | Liabeuf, Sophie, Laville, Solène M., Bieber, Brian, Tu, Charlotte, Stengel, Bénédicte, Wong, Michelle M.Y., Calice da Silva, Viviane, Fliser, Danilo, Robinson, Bruce M., Pecoits-Filho, Roberto, Massy, Ziad A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418947/ https://www.ncbi.nlm.nih.gov/pubmed/34514213 http://dx.doi.org/10.1016/j.ekir.2021.06.004 |
Ejemplares similares
-
Prescription of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care
por: Pecoits‐Filho, Roberto, et al.
Publicado: (2019) -
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
por: Massy, Ziad A., et al.
Publicado: (2019) -
Consequences of oral antithrombotic use in patients with chronic kidney disease
por: Laville, Solène M., et al.
Publicado: (2021) -
The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?
por: Essig, Marie, et al.
Publicado: (2020) -
The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much
por: Essig, Marie, et al.
Publicado: (2020)